Alaunos Therapeutics, Inc. announced that it has been accepted to present a proffered talk at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) being held in New York, NY from September 28 October 1, 2022. Details of the presentation are as follows: Title: Objective clinical response by KRAS mutation-specific TCR-T cell therapy in previously treated advanced Non-small cell lung cancer; Presenter: Marcelo V. Negrao, MD, Department of Thoracic-Head & Neck Med Onc, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center; Date and Time:Friday, September 30, 2022, 8:30am ET; Session Title: Session 6: Cellular Therapies: Engineering T cells.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.95 USD | -3.06% | -7.77% | -10.42% |
10/06 | BioSig Technologies Appoints Ferdinand Groenewald as Interim CFO | MT |
15/05 | Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-10.42% | 1.57Cr | |
+17.73% | 12TCr | |
+16.88% | 11TCr | |
-9.04% | 2.36TCr | |
+4.40% | 2.26TCr | |
-38.15% | 1.76TCr | |
-7.75% | 1.76TCr | |
-15.36% | 1.73TCr | |
+3.42% | 1.35TCr | |
+29.63% | 1.13TCr |
- Stock Market
- Equities
- TCRT Stock
- News Alaunos Therapeutics, Inc.
- Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference